Clinical Applications of Interleukin-37: A Key Player in the Immunopathogenesis of Immune Disorders

  • Elnaz Khosh GS PM School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  • Nazila Bahmaie GS PM Department of Allergy and Immunology, Faculty of Medicine, Graduate School of Health Science, Near East University (NEU), Nicosia, Northern Cyprus, Cyprus AND Medical Diagnosis Laboratory Expert, Private Baskent Hospital, Nicosia, Northern Cyprus, Cyprus
  • Reza Elahi GS PM School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  • Abdolreza Esmaeilzadeh ORCID GS PM Mail Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran AND Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran
Biomarkers, Human, Immune system diseases, Immunomodulation, Immunotherapy, Interleukin-37


Recently, the era of medicine has been encountered with the exponential growth of special seroimmunobiomarkers in clinical trials. Lately, Interleukin-37 (IL-37) has attracted a wide range of basic medical scientists’ attention due to its controversial functions in physiologic or pathologic microenvironments. In this research, an updated overview of immunobiological functions and clinical applications of IL-37 in a wide range of diseases, are discussed in order to highlight the role of recent laboratory-based results of IL-37.
Data of this systematic review article were collected from initial 237 articles in Google Scholar search engine, Science Direct, PubMed, Scopus, and Embase databases. Eventually, 134 total articles were considered from March 2000 to June 2019 time interval, by using 5 keywords. Relevant English articles, abstracts and conference papers all were included. No restrictions of methods and type of the article were imposed.
As one of the newly immunotherapeutic based approaches, clinical applications of cytokines are promisingly taken into account for diagnosis and treatment of multiple diseases. Various evidence suggests that IL-37 has notable roles in the regulation of acute and chronic inflammatory responses. Also, IL-37 has been studied in pregnancy, obesity, infectious, cardiovascular, neurologic, autoimmune, and metabolic diseases. Also, the protective functions of IL-37 against multiple cancers, are disputably related to the type and stage of cancer as well as the IL-37 variant.
The broad spectrum of IL-37 and its receptors in diseases, seem to be a potential candidate with pivotal effects for immunomodulation and immune gene therapy of various pathologic states.


1. Akdis M, Burgler S, Crameri R, Eiwegger T, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases.J Allergy Clin Immunol. 2011;127(3):701-21 e1-70. DOI: 10.1016/j.jaci.2010.11.050.
2. Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur cytokine netw. 2011;22(3):127-47. DOI:10.1684/ecn.2011.0288.
3. Wu W, Wang W, Wang Y, Li W, Yu G, Li Z, et al.
3IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-kappaB/S6K signalings. Acta Biochim Biophys Sin (Shanghai). 2015;47(8):597-603. DOI:10.1093/abbs/gmv058.
4. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11(11):1014-22. DOI: 10.1038/ni.1944.
5. Dinarello CA. Overview of the interleukin-1 family of ligands and receptors. Semin Immunol 2013;25(6):389-93. DOI:10.1016/j.smim.2013.10.001.
6. Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. PNAS USA. 2015;112(8):2497-502. DOI: 10.1073/pnas.1424626112.
7. Shuai X, Wei-min L, Tong YL, Dong N, Sheng ZY, Yao YM. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Sci rep. 2015;5:14478. DOI:
8. Tete S, Teripodp, Rosatp M, Contp F, Maccauro G, Saggini A, et al. IL-37 (IL':'lF7) The Newest
Anti-Inflammatory Cytokine Which Suppresses
Immune Responses and Inflammation. Int J Immunopathol Pharmacol. 2012;25(1):31-8. DOI: 10.1177/039463201202500105.
9. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014. DOI: :10.1371/journal.ppat.1004462.
10. Jia H, Liu J, Han B. Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases.Biomed Res Int. 2018;2018.DOI: 10.1155/2018/3058640.
11. Esmaeilzadeh A, Pouyan S, Erfanmanesh M. Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?. Med hypotheses. 2019;125:139-43.DOI: 10.1016/j.mehy.2019.02.048.
12. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL‐37. Immunol rev. 2018;281(1):179-90.DOI: 10.1111/imr.12605.
13. Günaltay S, Ghiboub M, Hultgren O, Hörnquist EH. Reduced IL-37 production increases spontaneous chemokine expressions in colon epithelial cells. Digest dis sci. 2017;62(5):1204-15.DOI: 10.1007/s10620-016-4422-9.
14. Hu D. Role of anti-inflammatory cytokines IL-35 and IL-37 in asthma. Inflammation. 2017 Apr 1;40(2):697-707.DOI: 10.1007/s10753-016-0480-6.
15. Wang L, Quan Y, Yue Y, Heng X, Che F. Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy. Oncol lett. 2018;15(4):4711-9.DOI: 10.3892/ol.2018.7982.
16. Yang T, Lin Q, Zhao M, Hu Y, Yu Y, Jin J, et al. IL-37 is a novel proangiogenic factor of developmental and pathological angiogenesis. Arterioscler thrombvasc biol. 2015:ATVBAHA. 115.306543.DOI: 10.1161/ATVBAHA.115.306543.
17. Lin X-Y, Guo X-J, He Y-Z, Hou S-F, Zhu H-B, Cheng Y, et al. Association between interleukin 37 (rs3811047) polymorphism and multiple autoimmune diseases in a Chinese population: A PRISMA-compliant meta-analysis. Medicine.2018;97(15).DOI:10.1097/MD.0000000000010386.
18. Liu J, Lin J, He S, Wu C, Wang B, Liu J, et al. Transgenic Overexpression of IL-37 Protects Against Atherosclerosis and Strengthens Plaque Stability. Cell Physiol Biochem. 2018;45(3):1034-50.DOI: 10.1159/000487344.
19. Xiao H, Li B, Yang X, Yin Q. IL-37 protects myocardial ischemia reperfusion injury in mice through mediating inflammation response. Biomed Res. 2018;29(4).DOI:10.4066/biomedicalresearch.29-17-1894.
20. Ballak DB, van Diepen JA, Moschen AR, Jansen HJ, Hijmans A, Groenhof GJ, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014 Sep 03;5:4711. PubMed PMID: 25182023.DOI: 10.1038/ncomms5711.
21. Southcombe JH, Redman CWG, Sargent IL, Granne I, . Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia. British Society for Immunology.J Clin Exp Immunol. 2015;181:480-90.DOI: 10.1111/cei.12608.
22. Manesh ME, Esmaeilzadeh A, Mirzaei MH. IL-24: A novel gene therapy candidate for immune system upregulation in Hodgkin’s lymphoma. Journal of Medical Hypothesis and Ideas.2015;9(1):61-6.DOI:10.1016/j.jmhi.2014.05.002.
23. Mazaheri T, Esmaeilzadeh A, Mirzaei MHKH. Introducing the immunomodulatory effects of mesenchymal stem cells in an experimental model of Behçet’s disease. Journal of Med Hypotheses and Ideas. 2012;6(1):23-7.DOI:10.1016/j.jmhi.2012.03.007.
24. Moghadam S, Erfanmanesh M, Esmaeilzadeh A. Interleukin 35 and Hepatocyte Growth Factor; as a novel combined immune gene therapy for Multiple Sclerosis disease. Med hypotheses. 2017;109:102-5.DOI: 10.1016/j.mehy.2017.09.017.
25. Bahmaie N, Faghihzadeh S, Esmaeilzadeh A, Amini B. Immunomodulatory Effects of Helicobacter Pylori on Pro and Anti-Inflammatory Cytokines Production in Peripheral Whole Blood Cells Culture. Biosci Biotech Res Asia. 2016 Dec 22;13(4):2221-30. DOI:
26. Piri Z, Esmaeilzadeh A, Hajikhanmirzaei M. Interleukin-25 as a candidate gene in immunogene therapy of pancreatic cancer.Journal of Medical Hypothesis
and Ideas. 2012;6(2):75-9.DOI:
27. Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Front Immunol. 2018;9.DOI: 10.3389/fimmu.2018.01717.
28. Ghasemi F, Sarabi PZ, Athari SS, Esmaeilzadeh A. Therapeutics strategies against cancer stem cell in breast cancer. Int J Biochem Cell Biol.2019;109:76-81.DOI: 10.1016/j.biocel.2019.01.015.
29. Khosh E, Bahmaie N, Esmaeilzadeh A. Evolution in Immune Gene Therapy of Glioblastoma; Interleukin-37 as a Novel Candidate. Clin Oncol. 2019;4:1618.
30. Bulau A-M, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. PNAS. 2014;111(7):2650-5.DOI: 10.1073/pnas.1324140111.
31. Nold-Petry CA, Lo CY, Rudloff I, Elgass KD, Li S, Gantier MP, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015 Apr;16(4):354-65. PubMed PMID: 25729923.DOI: 10.1038/ni.3103.
32. Li S, Amo-Aparicio J, Neff CP, Tengesdal IW, Azam T, Palmer BE, et al. Role for nuclear interleukin-37 in the suppression of innate immunity. PNAS. 2019;116(10):4456-61.DOI:
33. McNamee EN, Masterson JC, Jedlicka P, McManus M, Grenz A, Collins CB, et al. Interleukin 37 expression protects mice from colitis. PNAS USA. 2011;108(40):16711-6. DOI: 10.1073/pnas.1111982108.
34. Wang DW, Dong N, Wu Y, Zhu XM, Wang CT, Yao YM. Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4(+)CD25(+) Regulatory T Cells. Sci rep. 2016;6:38955.DOI: 10.1038/srep38955.
35. Quirk S, Agrawal DK. Immunobiology of IL-37: mechanism of action and clinical perspectives. Expert Rev Clin Immunol. 2014;10(12):1703-9. DOI:10.1586/1744666X.2014.971014.
36. Dinarello CA, Nold-Petry C, Nold M, Fujita M, Li S, Kim S, et al. Suppression of innate inflammation and immunity by interleukin-37. Eur JImmunol. 2016;46(5):1067-81. DOI: 10.1002/eji.201545828.
37. Alqazlan N, Diao H, Jevnikar AM, Ma S. Production of functional human interleukin 37 using plants. Plant cell rep. 2019:1-11.DOI: 10.1007/s00299-019-02377-2.
38. Zhou T, Sun Y, Wang Y, Chen X, Zhuo L, Bu L, et al. Umbilical Cord Blood Mesenchymal Stem Cells Enhance Lipopolysaccharide-Induced IL-10 and IL-37 Production in THP-1 Cells. Inflammation. 2019:1-7.DOI: 10.1007/s10753-019-00960-z.
39. Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-37 in cancer. Med oncol. 2016;33(7):68. DOI: 10.1007/s12032-016-0782-4.
40. Ye L, Jiang B, Deng J, Du J, Xiong W, Guan Y, et al. IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17–Triggering Cytokine Production and Limiting Th17 Cell Proliferation. J Immunol. 2015;194(11):5110-9.DOI: 10.4049/jimmunol.1401810.
41. Liu H, Zheng R, Wang P, Yang H, He X, Ji Q, et al. IL-37 confers protection against mycobacterial infection involving suppressing inflammation and modulating T cell activation. PloS one.2017;12(1):e0169922.DOI:10.1371/journal.pone.0169922.
42. Zhang J-A, Liu G-B, Zheng B-Y, Lu Y-B, Gao Y-C, Cai X-Z, et al. Tuberculosis-sensitized monocytes sustain immune response of interleukin-37. J Mol immunol. 2016;79:14-21.DOI:10.1016/j.molimm.2016.09.018.
43. Moretti S, Bozza S, Oikonomou V, Renga G, Casagrande A, Iannitti RG, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS pathog. 2014;10(11):e1004462.DOI:10.1371/journal.ppat.1004462.
44. Li W, Li S, Li X, Jiang S, Han B. Interleukin‐37 elevation in patients with atrial fibrillation. ClinCardiol. 2017;40(2):66-72.DOI:10.1002/clc.22630.
45. Yang T, Lin Q, Zhao M, Hu Y, Yu Y, Jin J, et al.
IL-37 is a novel proangiogenic factor of
developmental and pathological angiogenesis. ArteriosclerThrombVascBiol. 2015;35(12):2638-46.DOI:10.1161/ATVBAHA.115.306543.
46. Li C, Zhao P, Sun X, Che Y, Jiang Y. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome. Mediators inflamm. 2013;2013.DOI:10.1155/2013/639712.
47. Jiang J-F, Deng Y, Xue W, Zheng T-P, Sun A-J. Increased expression of interleukin 37 in the eutopic and ectopic endometrium of patients with ovarian endometriosis. Reprod Sci. 2016;23(2):244-8.DOI:10.1177/1933719115602775.
48. Kaabachi W, Kacem O, Belhaj R, Hamzaoui A, Hamzaoui K. Interleukin-37 in endometriosis. Immunol lett. 2017;185:52-5.DOI:10.1016/j.imlet.2017.03.012.
49. Jiang J, Jiang Z, Xue M. Serum and peritoneal fluid levels of interleukin-6 and interleukin-37 as biomarkers for endometriosis. J Gynecol Endocrinol. 2019;35(7):571-5.DOI:10.1080/09513590.2018.1554034.
50. Ballak DB, Stienstra R, Tack CJ, Dinarello CA, van Diepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75(2):280-90.DOI:10.1016/j.cyto.2015.05.005.
51. Conti P, Caraffa A, Ronconi G, Conti CM, Kritas SK, Mastrangelo F, et al. Impact of mast cells in depression disorder: inhibitory effect of IL-37 (new frontiers). ImmunolRes. 2018;66(3):323-31.DOI:10.1007/s12026-018-9004-9.
52. Weidlich S, Bulau AM, Schwerd T, Althans J,
Kappler R, Koletzko S, et al. Intestinal expression of the anti-inflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease. JPediatrGastroenterolNutr. 2014 Aug;59(2):e18-26. DOI:10.1097/MPG.0000000000000387.
53. Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease. Cytokine. 2015 Oct;75(2):389-402. DOI:10.1016/j.cyto.2015.04.009.
54. Weidlich S. Expression of Interleukin-37 in paediatric chronic inflammatory bowel disease. 2017.DOI:
55. Pastorelli L, Pizarro TT. Interleukin-37: A Peacekeeper at the Intestinal Borders. DigestDisSci. 2017 May;62(5):1103-6. DOI:10.1007/s10620-017-4523-0.
56. Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Ban H, Bamba S, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. J ClinExpImmunol. 2013;172:410-6.DOI: 10.1111/cei.12061.
57. Yan N, Meng S, Song RH, Qin Q, Wang X, Yao Q, et al. Polymorphism of IL37 gene as a protective factor for autoimmune thyroid disease. JMolEndocrinol. 2015 Dec;55(3):209-18. DOI:10.1530/JME-15-0144.
58. Ruggeri R, Cristani M, Vicchio T, Alibrandi A, Giovinazzo S, Saija A, et al. Increased serum interleukin-37 (IL-37) levels correlate with oxidative stress parameters in Hashimoto’s thyroiditis. J Endocrinol Invest. 2019;42(2):199-205.DOI: 10.1007/s40618-018-0903-3.
59. Zhao M, Hu Y, Yu Y, Lin Q, Yang J, Su SB, et al. Involvement of IL-37 in the Pathogenesis of Proliferative Diabetic Retinopathy. Invest Ophtalmol Vis Sci. 2016;57:2955-62.DOI:10.1167/iovs.15-18505.
60. Xia T, Zheng X-f, Qian B-h, Fang H, Wang J-j, Zhang L-l, et al. Plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. DisMarkers. 2015;2015.DOI:10.1155/2015/795043.
61. Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines. Cytokine. 2015;76(2):553-7.DOI:10.1016/j.cyto.2015.06.005.
62. Yang L, Zhang J, Tao J, Lu T. Elevated serum levels of I nterleukin‐37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. APMIS. 2015;123(12):1025-31.DOI:10.1111/apm.12467.
63. Ragab D, Mobasher S, Shabaan E. Elevated levels of IL-37 correlate with T cell activation status in rheumatoid arthritis patients. Cytokine. 2019;113:305-10.DOI:10.1016/j.cyto.2018.07.027.
64. Zhang G, Huang W, Wang Y. Detection of IL-37 in peripheral blood of patients with rheumatoid arthritis and its clinical significance. Eur J Inflamm. 2019;17:2058739218820221.DOI:10.1177/2058739218820221.
65. Yuan ZC, Wang JM, Huang AF, Su LC, Li SJ, Xu WD. Elevated expression of interleukin‐37 in patients with rheumatoid arthritis. IntJRheumDis. 2019.DOI:10.1111/1756-185X.13539.
66. El-Barbary AM, Hussein MS, Almedany SH, Rageh EM, Alsalawy AM, Aboelhawa MA, et al. Role of interleukin 37 as a novel proangiogenic factor in juvenile idiopathic arthritis. JClin Rheumatol. 2019;25(2):85-90.DOI:10.1097/RHU.0000000000000779.
67. Esmaeilzadeh A, Mohammadzadeh A, Bahmaie N. New Generation of Promising Immunotherapeutics Approaches for Psoriasis Dilemma; IL-35 Gene as a Potentiated Candidate. Inflamm Cell Signal. 2018;5.DOI:10.14800/ics.1635.
68. Sehat M, Talaei R, Dadgostar E, Nikoueinejad H, Akbari H. Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris.Iran JAllergy Asthma Immunol. 2018 Apr 28;17(2):179-87.PMID:29757591.
69. Ye Z, Wang C, Kijlstra A, Zhou X, Yang P. A possible role for interleukin 37 in the pathogenesis of Behcet's disease. CurrMolMed. 2014;14(4):535-42.DOI:10.2174/1566524014666140414210831.
70. Bouali E, Kaabachi W, Hamzaoui A, Hamzaoui K. Interleukin-37 expression is decreased in Behçet's disease and is associated with inflammation. ImmunolLett. 2015;167(2):87-94.DOI:10.1016/j.imlet.2015.08.001.
71. Tan H, Deng B, Yu H, Yang Y, Ding L, Zhang Q, et al. Genetic analysis of innate immunity in Behcet’s disease identifies an association with IL-37 and IL-18RAP. SciRep. 2016;6:35802.DOI:10.1038/srep35802.
72. Özgüçlü S, Duman T, Ateş FSÖ, Küçükşahin O, Çolak S, Ölmez Ü. Serum interleukin-37 level and interleukin-37 gene polymorphism in patients with Behçet disease. ClinRheumatol. 2019;38(2):495-502.DOI:10.1007/s10067-018-4288-7.
73. Ye L, Ji L, Wen Z, Zhou Y, Hu D, Li Y, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J TranslMed. 2014;12(69).DOI:10.1186/1479-5876-12-69.
74. TAWFIK MG, NASEF SI, OMAR HH, GHALY MS. Serum Interleukin-37: a new player in Lupus Nephritis? . Int J Rheum Dis. 2017.DOI:10.1111/1756-185X.13122.
75. Godsell J, Rudloff I, Kandane-Rathnayake R, Hoi A, Nold MF, Morand EF, et al. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci rep. 2016;6:34604.DOI:10.1038/srep34604.
76. Wu GC, Li HM, Wang JB, Leng RX, Wang DG, Ye DQ. Elevated plasma interleukin-37 levels in systemic lupus erythematosus patients. Lupus. 2016;25(12):1377-80.DOI:10.1177/0961203316646462.
77. Giacoppo S, Thangavelu SR, Diomede F, Bramanti P, Conti P, Trubiani O, et al. Anti-inflammatory effects of hypoxic-preconditioned human periodontal ligament cells secretome in an experimental model of multiple sclerosis: a key role of IL-37. FASEB J. 2017.DOI:10.1096/fj.201700524R.
78. Kouchaki E, Tamtaji OR, Dadgostar E, Karami M, Nikoueinejad H, Akbari H. Correlation of serum levels of IL-33, IL-37, soluble form of vascular endothelial growth factor receptor 2 (VEGFR2), and circulatory frequency of VEGFR2-expressing cells with multiple sclerosis severity.Iran J Allergy Asthma Immunol.. 2017;16(4):329-37.DOI:28865413.
79. Liu W, Deng L, Chen Y, Sun C, Wang J, Zhou L, et al. Anti-inflammatory effect of IL-37b in children with allergic rhinitis. Mediat Inflamm. 2014;2014:746846. P. DOI: 10.1155/2014/746846.
80. Li C, Shen Y, Wang J, Ma Z-X, Ke X, Wang Z-H, et al. Increased expression of IL-1R8 and a possible immunomodulatory role of its ligand IL-37 in allergic rhinitis patients. IntImmunopharmacol. 2018;60:152-9.DOI:10.1016/j.intimp.2018.04.002.
81. Zhu J, Dong J, Ji L, Jiang P, Leung TF, Liu D, et al. Anti-allergic inflammatory activity of interleukin-37 is mediated by novel signaling cascades in human eosinophils. Front Immunol. 2018;9:1445. DOI: 10.3389/fimmu.2018.01445.
82. Wang J, Shen Y, Li C, Liu C, Wang Z-H, Li Y-S, et al. IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis. IntImmunopharmacol. 2019;69:27-33.DOI:10.1016/j.intimp.2019.01.013.
83. Wegmann M. Targeting cytokines in asthma therapy: could IL-37 be a solution?. Expert Rev Respir Med. 2017 Sep;11(9):675-7. PubMed PMID: 28699819.DOI: 10.1080/17476348.2017.1354701.
84. Charrad R, Berraïes A, Hamdi B, Ammar J, Hamzaoui K, Hamzaoui A. Anti-inflammatory activity of IL-37 in asthmatic children: Correlation with inflammatory cytokines TNF-α, IL-β, IL-6 and IL-17A. Immunobiology. 2016;221(2):182-7.DOI:10.1016/j.imbio.2015.09.009.
85. Conti P, Ronconi G, Caraffa A, Lessiani G, Duraisamy K. IL-37 a new IL-1 family member emerges as a key suppressor of asthma mediated by mast cells. Immunol Invest. 2017 Apr 3;46(3):239-50.64.DOI: 1 0.1080/08820139.2016.1250220
86. Huang N, Liu K, Liu J, Gao X, Zeng Z, Zhang Y, et al. Interleukin-37 alleviates airway inflammation and remodeling in asthma via inhibiting the activation of NF-κB and STAT3 signalings. IntImmunopharmacol. 2018;55:198-204.65.DOI:10.1016/j.intimp.2017.12.010.
87. Zhao M, Hu Y, Shou J, Su SB, Yang J, Yang T. IL-37 impairs host resistance to Listeria infection by suppressing macrophage function. Biochem Biophys Res Commun. 2017;485(2):563-8. DOI:10.1016/j.bbrc.2016.11.002.
88. van de Veerdonk FL, Gresnigt MS, Oosting M, van der Meer JW, Joosten LA, Netea MG, et al. Protective host defense against disseminated candidiasis is impaired in mice expressing human interleukin-37. Front Microbiol. 2014;5:762. DOI:10.3389/fmicb.2014.00762.
89. Alves ABRM, David MA, de Castro LF, da Silva RM, Longhi LNA, Blotta MHdSL, et al. Differential production of interleukin-1 family cytokines (IL-1β, IL-18, IL-33 and IL-37) in patients with paracoccidioidomycosis: correlation with clinical form and antifungal therapy.Med Mycol. 2017;56(3):332-43.DOI:10.1093/mmy/myx050.
90 Li C, Ji H, Cai Y, Ayana DA, Lv P, Liu M, et al. Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment. JInterferon Cytokine Res. 2013;33.DOI:10.1089/jir.2013.0001.
91. Tsutsui H, Cai X, Hayashi S. Interleukin-1 family cytokines in liver diseases. Mediators Inflamm. 2015;2015.DOI:10.1155/2015/630265.
92. de Sousa JR, Prudente RL, Junior LB, Carneiro FR, Sotto MN, Quaresma JA. IL-37 and leprosy: A novel cytokine involved in the host response to Mycobacterium leprae infection. Cytokine. 2018 Jun 1;106:89-94.DOI:10.1016/j.cyto.2017.10.016.
93. Yin D, Naji DH, Xia Y, Li S, Bai Y, Jiang G, et al. Genomic variant in IL-37 confers a significant risk of coronary artery disease. SciRep. 2017;7:42175.DOI:10.1038/srep42175.
94. Chai M, Zhang H-T, Zhou Y-J, Ji Q-W, Yang Q, Liu Y-Y, et al. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. JGeriatr Cardiol. 2017;14(5):285.DOI:10.11909/j.issn.1671-5411.2017.05.013.
95. Hoeke G, Khedoe PP, van Diepen J, Pike-Overzet K, van de Ven B, Vazirpanah N, et al. The effects of selective hematopoietic expression of human IL-37 on systemic inflammation and atherosclerosis in LDLr-deficient mice. Int J Mol Sci.2017;18(8):1672.DOI:10.3390/ijms18081672.
96. Yan X, Xie B, Wu G, Hu J, Wang D, Cai X, et al. Interleukin-37: The Effect of Anti-Inflammatory Response in Human Coronary Artery Endothelial Cells. Mediators Inflamm. 2019;2019.DOI:10.1155/2019/2650590.
97. Ji Q, Meng K, Yu K, Huang S, Huang Y, Min X, et al. Exogenous interleukin 37 ameliorates atherosclerosis via inducing the Treg response in ApoE-deficient mice. SciRep. 2017;7(1):3310.DOI:10.1038/s41598-017-02987-4.
98. Zhuang X, Wu B, Li J, et al. The emerging role of interleukin-37 in cardiovascular diseases. Immun Inflamm Dis.2017;5(3):373-9.DOI:10.1002/iid3.159.
99. Ji Q, Zeng Q, Huang Y, Shi Y, Lin Y, Lu Z, et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome.Mediators Inflamm. 2014;2014.DOI:10.1155/2014/165742.
100. Wu B-w, Zeng Q-t, Meng K, Ji Q-w. The potential role of IL-37 in atherosclerosis. Die Pharmazie-AnPharmazie. 2013;68(11):857-60.PMID: 24380232.
101. Xu J, Luo X, Guo L, Han S. Protective mechanism of IL-37 in the regulation of Tregs in myocardial ischemia microcirculation reperfusion injury.Int J Clin Exp Pathol.2016;9(4):4810-5. DOI:
102. Zhu R, Sun H, Yu K, Zhong Y, Shi H, Wei Y, Su X,
Xu W, Luo Q, Zhang F, Zhu Z. Interleukin‐37 and dendritic cells treated with interleukin‐37 plus troponin I ameliorate cardiac remodeling after myocardial infarction.J Am Heart Assoc. 2016 Dec 5;5(12):e004406.DOI:10.1161/JAHA.116.004406.
103. Wu B, Meng K, Ji Q, Cheng M, Yu K, Zhao X, et al. Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. J Clin Exp Immunol. 2014;176(3):438-51.DOI:10.1111/cei.12284.
104. Xu J, Luo X, Guo L, Han S. Protective mechanism of IL-37 in the regulation of Tregs in myocardial ischemia microcirculation reperfusion injury. Int J Clin Exp Pathol.2016;9(4):4810-5.DOI:
105. Chai M, Zhang HT, Zhou YJ, Ji QW, Yang Q, Liu YY, et al. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. JGeriatr Cardiol. 2017;14(5):285-91. DOI:10.11909/j.issn.1671-5411.2017.05.013.
106. Shou X, Lin J, Xie C, Wang Y, Sun C. Plasma IL-37 Elevated in Patients with Chronic Heart Failure and Predicted Major Adverse Cardiac Events: A 1-Year Follow-Up Study. Dis Markers. 2017;2017:1-6.DOI:10.1155/2017/9134079.
107. Chai M, Ji Q, Zhang H, Zhou Y, Yang Q, Zhou Y, et al. The protective effect of interleukin-37 on vascular calcification and atherosclerosis in apolipoprotein E-deficient mice with diabetes. J Interferon Cytokine Res. 2015;35(7):530-9.DOI:10.1089/jir.2014.0212.
108. Yu K, Min X, Lin Y, Huang Y, Huang S, Liu L, et al. Increased IL-37 concentrations in patients with arterial calcification.Clin Chim Acta.2016;461:19-24.DOI:10.1016/j.cca.2016.07.011.
109. Zeng Q, Song R, Fullerton DA, Ao L, Zhai Y, Li S, et al. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice.Proc Natl Acad Sci U S A.2017;114(7):1631-6.DOI:10.1073/pnas.1619667114.
110. Zan Q, Zeng Q, Song R, Zhai Y, Xu D, Fullerton DA, et al. IL-37 Suppresses MyD88-mediated Inflammatory Responses in Human Aortic Valve Interstitial Cells. Mol Med. 2017;23:83.DOI: 10.2119/molmed.2017.00022.
111. Yu Z, Liu J, Zhang R, et al. IL-37 and 38 signalling in gestational diabetes. J Reprod Immunol. 2017;124:8-14.DOI: 10.1016/j.jri.2017.09.011.
112. Wang P, Wang H, Li C, Zhang X, Xiu X, Teng P, et al. Dysregulation of microRNA‐657 influences inflammatory response via targeting interleukin‐37 in gestational diabetes mellitus. J Cell Physiol. 2019;234(5):7141-8.DOI:10.1002/jcp.27468.
113. Conti P, Ronconi G, Kritas SK, Caraffa A, Theoharides TC. Activated mast cells mediate low-grade inflammation in type 2 diabetes: Interleukin-37 could be beneficial.
Can J Diabetes. 2018;42(5):568-73. DOI:10.1016/j.jcjd.2018.01.008.
114. Jiang JF, Xiao SS, Xue M. Decreased expression of interleukin-37 in the ectopic and eutopic endometria of patients with adenomyosis. Gynecol Endocrinol. 2017 Aug 1:1-4. DOI:10.1080/09513590.2017.1354367.
115. Coll Miró M. Therapeutic role of IL‐37 after injury to the nervous system. Universitat Autònoma de Barcelona; 2015.
116. Wan Z-Y, Sun Z, Song F, Chen Y-F, Zhang W-L, Wang H-Q, et al. Downregulated interleukin 37 expression associated with aggravation of intervertebral disc degeneration. Int J Clin Exp Pathol.2014;7(2):656.PMCID:PMC3925910.
117. Hajikhan Mirzaei M, Esmaeilzadeh A. Overexpression of MDA-7/IL-24 as an anticancer cytokine in gene therapy of thyroid carcinoma. Journal of Medical Hypothesis and Ideas.2014;8(1):7-13.DOI:10.1016/j.jmhi.2013.06.002.
118. Liu R, Tang C, Shen A, Luo H, Wei X, Zheng D,
et al. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21
tumor-suppressive signaling. Oncotarget. 2016;7(51):85079.DOI:10.18632/oncotarget.13196.
119. Li Y, Zhao M, Guo C, Chu H, Li W, Chen X, et al. Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation. Oncogene. 2018;37(8):1095.DOI:10.1038/onc.2017.
120. Zhao J-J, Pan Q-Z, Pan K, Weng D-S, Wang Q-J, Li J-J, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. SciRep. 2014;4.DOI:10.1038/srep05177.
121. Davis CJ, Zielinski MR, Dunbrasky D, Taishi P, Dinarello CA, Krueger JM. Interleukin 37 expression in mice alters sleep responses to inflammatory agents and influenza virus infection. Neurobiol Sleep Circadian Rhythms.. 2017;3:1-9.DOI:10.1016/j.nbscr.2016.11.005.
122. Jiang Y, Wang Y, Liang L, Gao Y, Chen J, Sun Y, et al. IL-37 mediates the antitumor activity in renal cell carcinoma. Med Oncol. 2015 Nov;32(11):250. DOI:10.1007/s12032-015-0695-7.
123. Deng YM, Zhang H, Liang JM, Xian HB, Chen ZC, Tang YC, Yang S, Feng WN. IL-37 mediates the anti-tumor activity in non-small cell lung cancer through IL-6/STAT3 pathway. J Appl Biomed. 2018 Feb 1;16(1):15-21.DOI:10.1016/j.jab.2017.04.001.
124. Jiang M, Wang Y, Zhang H, Ji Y, Zhao P, Sun R, et al. IL‐37 inhibits invasion and metastasis in non‐small cell lung cancer by suppressing the IL‐6/STAT3 signaling pathway.Thorac Cancer. 2018;9(5):621-9.DOI:10.1111/1759-7714.12628.
125. Ge G, Wang A, Yang J, al e. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in nonsmall cell lung cancer. J Exp Clin Cancer Res.2016;35(13).DOI:10.1186/s13046-016-0293-3.
126. Wang W-q, Zhao D, Zhou Y-s, Hu X-y, Sun Z-n, Yu G, et al. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer. Acta Pharmacol Sin. 2015;36(4):528-34.DOI:10.1038/aps.2015.3.
127. Wang S, An W, Yao Y, Chen R, Zheng X, Yang W, et al. Interleukin 37 expression inhibits STAT3 to suppress the proliferation and invasion of human cervical cancer cells. JCancer. 2015;6(10):962.DOI:10.7150/jca.12266.
128. Yan X, Zhao J, Zhang R. Interleukin-37 mediates the antitumor activity in colon cancer through β-catenin suppression. oncotarget. 2017;8(30).DOI:10.18632/oncotarget.17093.
129. Lin L, Wang J, Liu D, Liu S, Xu H, Ji N, et al. Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma. Sci Rep. 2016 May 26;6:26757. DOI:10.1038/srep26757.
130. Li ZC, Sun MD, Zheng YQ, Fu HJ. The Low
Expression of IL-37 Involved in Multiple Myeloma–Associated Angiogenesis. Med Sci Monit. 2016;22:4164.131.DOI:10.12659/MSM.897451.
131. Chen Y-H, Zhou B-Y, Wu X-J, Zhang J-A, Chen Y-H, Di X-Q, et al. CD4+CD25+Foxp3+ regulated T cells and expression of IL-37 and chemokine ligand 2 in lung cancer and their clinical significance. Int J Clin Exp Pathol. 2016;9(2):866-76.IJCEP0017562.
132. Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Arch Gynecol Obstet. 2017 Feb;295(2):459-65. PubMed PMID: 27975129.DOI:10.1007/s00404-016-4258-8.
133. Ding VA, Zhu Z, Steele TA, Wakefield MR, Xiao H, Balabanov D, et al. The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer. Med Oncol. 2018;35(1):6.DOI:10.1007/s12032-017-1070-7.
134. Sağlam M, Köseoğlu S, Savran L, Pekbağriyanik T, Sağlam G, Sütçü R. Levels of interleukin‐37 in gingival crevicular fluid, saliva, or plasma in periodontal diseaseJ Periodontal Res. 2015;50(5):614-21.DOI:10.1111/jre.12241.
External links
PMID: 32615656
How to Cite
Khosh E, Bahmaie N, Elahi R, Esmaeilzadeh A. Clinical Applications of Interleukin-37: A Key Player in the Immunopathogenesis of Immune Disorders. Iran J Allergy Asthma Immunol. 19(3):209-228.
Review Article(s)